Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2021 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
February 19, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
January 05, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
November 13, 2020 08:05 ET | Source: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Additional data from SIGNAL Huntington’s disease (HD) trial support continued development in HD and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA®...
October 29, 2020 11:15 ET | Source: Vaccinex, Inc.

CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in...
October 29, 2020 07:55 ET | Source: Vaccinex, Inc.

Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
October 26, 2020 07:55 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable

ROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
September 22, 2020 07:30 ET | Source: Vaccinex, Inc.

Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...
September 17, 2020 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease...
August 27, 2020 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer

ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right